Could These 2 Biotech Stocks Really Double Your Money?
Investment-bank analysts have been slapping lofty price targets on small-cap biotech stocks recently. More than a few targets I've seen recently suggest you could easily double your money or better.
Before you plunk down any of your hard-earned savings, it's important to understand a couple of things about biotech stock price targets. First, high targets get more attention and less hate mail, so you should always take them with a grain of salt. Also, arriving at a price target generally involves some fancy math to account for the odds an upcoming catalyst will spark a huge rally or lead to a vicious sell-off.
Adamas Biopharmaceuticals Inc. (NASDAQ: ADMS), and Insmed Incorporated (NASDAQ: INSM) face some pretty big catalysts that could more than double their prices, according to some investment-bank analysts. Here's a look at what needs to go right, and what could go wrong.
Source: Fool.com
Insmed Inc. Stock
The stock is an absolute favorite of our community with 42 Buy predictions and no Sell predictions.
With a target price of 75 € there is a slightly positive potential of 10.29% for Insmed Inc. compared to the current price of 68.0 €.
